163061-19-6

Basic information

• Product Name: N-BOC-L-PHENYLGLYCINAL
• Synonyms: N-BOC-L-PHENYLGLYCINAL;N-t-BOC-L-Phenylglycinal;Boc-L-phenylglycinal;(S)-tert-butyl 2-oxo-1-phenylethylcarbamate
• CAS NO: 163061-19-6
• Molecular Formula: C₁₃H₁₇NO₃
• Molecular Weight: 235.27898
• Mol File: 163061-19-6.mol

Chemical Properties

• Boiling Point: 356.67 °C at 760 mmHg
• Flash Point: 169.508 °C
• Appearance: /
• Density: 1.093 g/cm³
• CAS DataBase Reference: N-BOC-L-PHENYLGLYCINAL(CAS DataBase Reference)
• NIST Chemistry Reference: N-BOC-L-PHENYLGLYCINAL(163061-19-6)
• EPA Substance Registry System: N-BOC-L-PHENYLGLYCINAL(163061-19-6)

Safety Data

• Hazard Codes: Xn
• Statements: 20/21/22-36/37/38-43
• Safety Statements: 26
• Hazardous Substances Data: 163061-19-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-BOC-L-PHENYLGLYCINAL is used as an intermediate in the production of pharmaceuticals for its Boc-protected amine group, which facilitates peptide synthesis. Its reactivity and versatility in organic synthesis make it a valuable starting material for the synthesis of various drugs and pharmaceutical compounds.
Used in Medicinal Chemistry Research:
N-BOC-L-PHENYLGLYCINAL is used as a research chemical in laboratories, where it contributes to the development of new drugs and pharmaceutical compounds. Its potential applications in medicinal chemistry and drug development make it an essential tool for researchers in the field.
Used in Drug Synthesis:
N-BOC-L-PHENYLGLYCINAL is used as a starting material for the synthesis of various drugs and pharmaceutical compounds due to its reactivity and versatility in organic synthesis. Its Boc-protected amine group allows for efficient peptide synthesis, making it a crucial component in the development of new therapeutic agents.

Upstream product

• 117049-14-6 tert-butyl N-[(1S)-2-hydroxy-1-phenylethyl]carbamate 
• 143978-88-5 N-tert-butoxycarbonyl-L-phenylglycine methyl ester 
• 757195-52-1 tert-butyl (1S)-2,3-dihydroxy-1-phenylpropylcarbamate 
• 20989-17-7 (2S)-2-phenylglycinol 
• 335627-66-2 (4S,5R)-5-benzyloxy-4-phenyl-2-oxazolidinone 
• 6591-61-3 (S)-Phenylglycine methyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 502157-97-3 (2S)-2-phenyl-2-({[(1R)-1-phenyl-2-propenyl]amino}oxy)ethanol 
• 158851-29-7 (+)-tert-butyl [(1R)-1-phenylprop-2-en-1-yl]imidocarbonate 
• 368447-65-8 benzaldehyde (E)-O-[(1S)-2-hydroxy-1-phenylethyl]oxime 
• 325490-29-7 (1R)-1-phenylprop-2-en-1-amine 
• 15028-39-4 L-2-phenylglycine methyl ester hydrochloride 
• 2935-35-5 (S)-2-phenylglycine 
• 2900-27-8 (2S)-2-[(tert-butoxycarbonyl)amino]-2-phenylethanoic acid 

Downstream Products

• 499783-32-3 ((S)-2-Hydroxy-3-nitro-1-phenyl-3-p-tolylsulfanyl-propyl)-carbamic acid tert-butyl ester 
• 216769-56-1 (2E,4R)-4-(t-butoxycarbonylamino)-4-phenylbutenbutenoic acid methyl ester 
• 879219-16-6 [2-(5-fluoro-2,3-dihydro-indol-1-yl)-1-phenyl-ethyl]-carbamic acid tert-butyl ester 
• 949925-79-5 (S)-2-Amino-N-((S)-2-ethylcarbamoyl-2-hydroxy-1-phenyl-ethyl)-3-methyl-butyramide 
• 949926-06-1 5-[1,2]Dithiolan-3-yl-pentanoic acid [(S)-1-((S)-2-ethylcarbamoyl-2-hydroxy-1-phenyl-ethylcarbamoyl)-2-methyl-propyl]-amide 
• 160237-87-6 (1S,2S)-1-<(tert-butoxycarbonyl)amino>-2-hydroxy-1-phenyl-4-pentene 
• 117049-14-6 tert-butyl N-[(1S)-2-hydroxy-1-phenylethyl]carbamate 
• 257296-52-9 (E)-(R)-4-tert-Butoxycarbonylamino-4-phenyl-but-2-enoic acid ethyl ester 
• 67341-01-9 (R)-N-(tert-butoxycarbonyl)phenylglycinol 
• 1013421-37-8 tert-butyl (1S,2R)-2-hydroxy-1-phenylpent-4-enylcarbamate 
• 136693-07-7 1,1-dimethylethyl (N-((1S,2R)-2-hydroxy-1-phenyl-3-butenyl)amino)methanoate 
• 136693-03-3 (+)-1,1-dimethylethyl (N-((1S,2S)-2-hydroxy-1-phenyl-3-butenyl)amino)methanoate 
• 104700-39-2 (E)-ethyl 4-(tert-butoxycarbonylamino)-4-phenylbut-2-enoate 

Relevant articles and documents

ERK INHIBITORS

The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are ERK2 inhibitors. The invention also provides a method of inhibiting ERK2 in a patient in need of such treatment comprising administering to said patient an effective amount of at least one compound of Formula (I). The invention also provides a method for treating cancer in a patient in need of such treatment, said method comprising administering to said patient an effective amount of at least one compound of Formula (I).

A rapid and efficient one-pot method for the reduction of N-protected α-amino acids to chiral α-amino aldehydes using CDI/DIBAL-H

N-Protected amino acids can be easily converted into chiral α-amino aldehydes in a one-pot reaction by activation with CDI followed by reduction with DIBAL-H. This method delivers Boc-, Cbz- and Fmoc-protected amino aldehydes from proteinogenic amino acids in very good isolated yields and complete stereointegrity.

Synthesis of tetrasubstituted symmetrical pyrazines from β-keto γ-amino esters: A mild strategy for self-dimerization of peptides

A facile synthesis of highly symmetrical tetrasubstituted pyrazines through simple aerial oxidation of β-keto γ-amino esters is reported. The scope of the reaction was examined by use of various amino acid side-chain functional groups andpeptides. The mil

New routes towards reutericyclin analogues

A range of N-acylpyrrolo[3,4-c]isoxazoles and derived N-acyltetramides has been prepared via a nitrile oxide dipolar cycloaddition approach, as analogues of the acyltetramic acid metabolite reutericyclin, of interest for its antibiotic potential against G

Hypervalent iodine/TEMPO-mediated oxidation in flow systems: A fast and efficient protocol for alcohol oxidation

Hypervalent iodine(III)/TEMPO-mediated oxidation of various aliphatic, aromatic and allylic alcohols to their corresponding carbonyl compounds was successfully achieved by using microreactor technology. This method can be used as an alternative for the oxidation of various alcohols achieving excellent yields and selectivities in significantly shortened reaction times.

Arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 2: Optimization of P1 and N-aryl

A systematic study of anilines led to the discovery of a metabolically robust fluoroindoline replacement for the alkoxy aniline toxicophore in 1. Investigations of the P1 pocket resulted in the discovery of a wide tolerance of functionality leading to the discovery of 11 as a potent and selective inhibitor of cathepsin S.

Enantiospecific formation of 3,6-dihydro-1H-pyridin-2-ones: Low-pressure palladium-catalysed decarboxylative carbonylation of 3-tosyl-5-vinyloxazolidin- 2-ones

Palladium-catalysed decarboxylative carbonylation of 3-tosyl-5- vinyloxazolidin-2-ones 5 occurs at atmospheric pressure to give 1-tosyl-3,6-dihydro-1H-pyridin-2-ones 6. The reaction proceeds with no loss of enantiopurity and detosylation with sodium napht

PROCESS FOR PREPARING OXAZOLIDINE DERIVATIVES

A process for preparing (4S,5R)-5-carboxymethyl-2,2-dimethyl-4-phenyl-oxazolidine-3-carboxylic acid t-butyl ester, an intermediate in the preparation of anticancer compounds having a taxane skeleton, such as paclitaxel, docetaxol, etc.

Allylation of aldehydes and imines: Promoted by reuseable polymer-supported sulfonamide of N-glycine

A allylation of aldehydes and imines (generated in situ from aldehydes and amines) with allyltributyltin promoted by recoverable and reusable the polymer-supported sulfonamide of N-glycine has been developed. Good to high yields were obtained in various cases. Most of the SnBu3 residue can be recovered as Bu3SnCl. Highly stereoselective synthesis of N-Boc-(2S,3S)-3-hydroxy-2-phenylpiperidine 7 was achieved by using the P4a-mediated allylation of Boc-L-phenylglycinal as a key step.

A direct and efficient stereoconservative procedure for the selective oxidation of N-protected β-amino alcohols

An efficient, very simple and eco-friendly procedure has been developed for the synthesis of highly enantioenriched α-amino aldehydes by IBX-mediated oxidation of the corresponding β-amino alcohols. The procedure has been applied to a wide range of substr